Halper Sadeh LLC is investigating whether officers and directors of Kyverna Therapeutics breached their fiduciary duties to shareholders. Long-term shareholders of Kyverna stock may seek corporate reforms, financial awards, or other relief. The law firm offers free consultations and works on a contingency fee basis, meaning no upfront legal fees for shareholders. Immediate contact is advised due to potential time limits on enforcing rights.
Regarding the investigation into Kyverna Therapeutics, Inc. insiders and their fiduciary duties, here is Pluang's health sector market snapshot as of Oct 23, 2026 00:41 WIB: Out of 150 priced US health stocks, 79 rose and 70 fell today. Notable movers include TWST at USD 133.15 with a 1-day change of -10.72% and Pluang order activity of 7% Sell / 93% Buy, TXG at USD 68.47 down 9.42% with 0% Sell / 100% Buy, and NUWE at USD 0.48 down 7.98% with 0% Sell / 100% Buy. The most notable figure is TWST's 93% buy order activity on Pluang.
Share-ify introduced the S.A.F.E. Score™, an AI-powered forecasting engine designed to enhance supplier risk intelligence within its food safety and compliance solutions. This tool analyzes diverse data such as audit results, recall history, and insp...
EquipmentShare, a major U.S. construction equipment rental and technology provider, will announce its fiscal third quarter 2026 financial results after market close on November 9, 2026. The company will host a conference call for investors and analys...
Atlantic American Corporation received a Nasdaq Staff Delisting Determination due to missing its 2025 annual and 2026 quarterly SEC reports by the extended October 12 deadline. The company has since filed the 2025 annual report and is working to subm...
Randstad reported revenue and earnings that exceeded expectations, driven by improving business trends and key labor markets. This positive performance signals momentum in the employment services sector. RBC Capital maintained a 'Sector Perform' rati...
MSC Industrial Supply reported strong Q4 results with revenue rising 10.3% year-over-year to about $1.08 billion, surpassing estimates. Adjusted earnings per share increased to $1.45 from $1.09, also beating expectations. Full-year sales grew 6.4% to...
